Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

32097

Supelco

Etoricoxib

VETRANAL®, analytical standard

Synonym(s):

5-Chloro-3-[4-(methylsulfonyl)phenyl]-2-(2-methyl-5-pyridinyl)pyridine, 5-Chloro-6′-methyl-3-[4-(methylsulfonyl)phenyl]-2,3′-bipyridine

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C18H15ClN2O2S
CAS Number:
202409-33-4
Molecular Weight:
358.84
Beilstein:
8073797
MDL number:
MFCD06797512
UNSPSC Code:
41116107
PubChem Substance ID:
329753738
NACRES:
NA.24

grade

analytical standard

Quality Level

100

product line

VETRANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

format

neat

storage temp.

2-8°C

SMILES string

CC1=NC=C(C2=C(C3=CC=C(S(C)(=O)=O)C=C3)C=C(Cl)C=N2)C=C1

InChI

1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3

InChI key

MNJVRJDLRVPLFE-UHFFFAOYSA-N

Gene Information

human ... PTGS2(5743)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Etoricoxib is a non-steroidal cyclooxygenase-2 (COX-2) selective anti-inflammatory drug mostly used to treat patients suffering from osteoarthritis and rheumatoid arthritis.

Application

Etoricoxib may have been used as reference standard in liquid chromatography-tandem mass spectrometry method with atmospheric pressure chemical ionization (LC-APCI/MS/MS) method for determination of etoricoxib from human plasma.
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Legal Information

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H302,H310

Hazard Classifications

Acute Tox. 2 Dermal - Acute Tox. 4 Oral

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCM4253
BCCM3026
BCCK9569
BCCF5705
BCCB6900

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 3

1 of 3

Tinidazole VETRANAL®, analytical standard

Supelco

32553

Tinidazole

Valsartan Related Compound C Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1877

Valsartan Related Compound C

vibrant-m

Y0000751

Fexofenadine impurity A,

Determination of etoricoxib in human plasma using automated on-line solid-phase extraction coupled with LC-APCI/MS/MS.
Dalmora, Sergio Luiz, et al.
Quimica nova, 31.3, 574-578 (2008)
Rik J Lories
Expert opinion on drug metabolism & toxicology, 8(12), 1599-1608 (2012-11-07)
Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line therapies in the management of patients with ankylosing spondylitis. This chronic inflammatory skeletal disorder, a subtype of spondyloarthritis, is characterized by inflammatory back pain and affects young adults causing important suffering and disability. Long-term
Rachel Clarke et al.
The Cochrane database of systematic reviews, (2)(2), CD004309-CD004309 (2009-04-17)
Etoricoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor prescribed for the relief of chronic pain in osteoarthritis and rheumatoid arthritis, and acute pain. The drug is believed to be associated with fewer upper gastrointestinal adverse effects than conventional non-steroidal anti-inflammatory drugs
Eugene R Viscusi et al.
Current medical research and opinion, 28(8), 1323-1335 (2012-06-29)
To evaluate the effects of two different doses of etoricoxib delivered perioperatively compared with placebo and standard pain management on pain at rest, pain with mobilization, and use of additional morphine/opioids postoperatively. In this double-blind, placebo-controlled, randomized clinical trial, we
Paola Patrignani et al.
Expert opinion on pharmacotherapy, 4(2), 265-284 (2003-02-04)
The development of COX2 inhibitors with improved biochemical selectivity (such as etoricoxib and valdecoxib) over that of commercially available coxibs has been driven by the potential advantage of safety using higher coxib doses for increased efficacy. Etoricoxib has been approved
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service